[e-farmacos] WHO Pharmaceuticals Newsletter n5 2004

["Canas, Martin" <macanas@netverk.com.ar>]

Estimadas y estimados,

Esta disponible el ultimo numero del WHO Pharmaceuticals Newsletter numero 5
del 2004

http://www.who.int/medicines/library/pnewslet/5news2004.pdf

Tiene el siguiente contenido:

REGULATORY MATTERS
ANTIDEPRESSANTS -- Labels to include enhanced warnings  1
ARISTOLOCHIC ACID -- To be replaced by Stephania tetrandra and Inula
helenium 1
ENOXAPARIN -- Dosage adjustment needed in patients with renal impairment 1
INFLIXIMAB -- Label to reflect haematological and neurological events 2
LEVOTHYROXINE -- Changes to regulatory status 2
PHU CHEE/LIN CHEE/ACTIVE RHEUMA PLUS -- Banned due to presence of undeclared
glucocorticoids2
PHENYLPROPANOLAMINE -- Banned in Korea2
RIFAMPICIN/PYRAZINAMIDE -- Revised advice 3
ZIPRASIDONE -- Updated prescribing information 3

SAFETY OF MEDICINES
BEVACIZUMAB -- Increased risk of thromboembolic events 4
CLOPIDOGREL -- Reports of haemorrhagic events 4
LAMOTRIGINE -- Interaction with hormonal contraceptives 4
NITROFURANTOIN -- Risk of lung toxicity with long-term use 4
RITUXIMAB -- Possible association with Hepatitis B reactivation5
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) -- Potential adverse effects
in neonates 5
WARFARIN -- Interaction with fluoroquinolones 5
WARFARIN -- Interaction with tramadol 6

DRUGS OF CURRENT INTEREST
CYCLOOXYGENASE - 2 INHIBITORS 7
FEATURE
"WHO training workshop on introducing pharmacovigilance into HIV/AIDS
programmes" 8


 Saludos,

 Martin

 Martin Canas
 La Plata
 (Argentina)
 macanas@netverk.com.ar